# A Clinical Trial of TQB3909 Tablets Combined With TQB3702 Tablets in Patients With Hematologic Malignancy

> **NCT06211751** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 208 (estimated)

## Conditions studied

- Hematologic Malignancy

## Interventions

- **DRUG:** TQB3909 tablets
- **DRUG:** TQB3702 tablets

## Key facts

- **NCT ID:** NCT06211751
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-01
- **Primary completion:** 2025-12
- **Final completion:** 2026-06
- **Target enrollment:** 208 (ESTIMATED)
- **Last updated:** 2024-01-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06211751

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06211751, "A Clinical Trial of TQB3909 Tablets Combined With TQB3702 Tablets in Patients With Hematologic Malignancy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06211751. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*